跳至主要内容
临床试验/NCT06807905
NCT06807905已完成4 期

Prospective, Interventional Study to Iivestigate the Efficiency and Biocompatibility in Hemodiafiltration Procedure

University Medical Centre Ljubljana1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年2月1日最近更新:
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
20
试验地点
1
主要终点
removal of small and medium molecules

研究概览

简要总结

Hemodiafiltration is a modern, increasingly used special hemodialysis method. Compared to hemodialysis, it allows greater clearance of medium- and high-molecular-weight molecules. Modern hemofiltration membranes are approaching the properties of the glomerular membrane in their properties.

During hemodiafiltration, blood contact with the semipermeable membrane and blood lines causes activation of the coagulation system, so anticoagulation during the procedure is absolutely necessary. Heparin is routinely used as a method of anticoagulation in hemodiafiltration. Regional citrate anticoagulation is used primarily in patients with risk of bleeding.

The purpose of our study is to evaluate the kinetics of citrate, calcium, and magnesium during hemodiafiltration and citrate anticoagulation, and in these way optimizing the citrate anticoagulation protocol during hemodiafiltration, and to compare the clearance of small and medium molecules between the two anticoagulations (citrate and heparin). The purpose of the study is also to compare biocompatibility parameters for heparin and citrate anticoagulation in hemodiafiltration.

详细描述

Aim of the study

Hemodiafiltration is a modern, increasingly used special hemodialysis method. Compared to hemodialysis, it allows greater clearance of medium- and high-molecular-weight molecules. Modern hemofiltration membranes are approaching the properties of the glomerular membrane in their properties.

During hemodiafiltration, blood contact with the semipermeable membrane and blood lines causes activation of the coagulation system, so anticoagulation during the procedure is absolutely necessary. Heparin is routinely used as a method of anticoagulation in hemodiafiltration. Regional citrate anticoagulation is used primarily in patients with risk of bleeding.

The purpose of our study is to evaluate the kinetics of citrate, calcium, and magnesium during hemodiafiltration and citrate anticoagulation, and in these way optimizing the citrate anticoagulation protocol during hemodiafiltration, and to compare the clearance of small and medium molecules between the two anticoagulations (citrate and heparin). The purpose of the study is also to compare biocompatibility parameters for heparin and citrate anticoagulation in hemodiafiltration.

Hypothesis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CKD on dialysis

排除标准

  • AKI on dialysis
  • patients on anticoagulant therapy
  • systemic bacterial infection

研究组 & 干预措施

Heparin anticoagulation

Active Comparator

Heparin anticoagulation in hemodiafiltration procedure

干预措施: Heparin anticoagulation (Drug)

Citrate anticoagulation

Experimental

Hemodiafiltration will be performed with regional citrate anticoagulation

干预措施: Citrate anticoagulation (Drug)

结局指标

主要结局

removal of small and medium molecules

时间窗: during 4 hour dialysis

The removal of small and medium molecules is different comparing citrate and heparin anticoagulation.

次要结局

  • biocompatibility(during 4 hour dialysis)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Milena Andonova

MD

University Medical Centre Ljubljana

研究点 (1)

Loading locations...

相似试验